Successful, we will reply to you quickly.


Please select the quantity.


Your message is being sent, please wait.




Send mail failed, please send again!


Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway



(SU 11274; PKI-SU11274; SU-11274)


SU11274 Chemical Structure

SU11274(PKI-SU11274) is a selective Met inhibitor with IC50 of 10 nM, no effects on PGDFRβ, EGFR or Tie2.

Price and Availability of SU11274

  • Select country:
  • America
  • Europe
  • Others
Size Price Stock Quantity
10 mM * 1 mL $169 In-stock
10 mg $154 In-stock
50 mg $564 In-stock
100 mg $715 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL €166 In-stock
10 mg €151 In-stock
50 mg €553 In-stock
100 mg €701 In-stock
200 mg Get quote
500 mg Get quote

Discount Prices Available for Larger Orders.

SU11274 Data Sheet

  • View current batch:

    Purity: 98.56%

  • Pdf Version Network Version


    Pdf Version Network Version


    Pdf Version


    Pdf Version


    Pdf Version


Customer View

Related Compound Libraries

Biological Activity of SU11274

SU11274(PKI-SU11274) is a selective Met inhibitor with IC50 of 10 nM, no effects on PGDFRβ, EGFR or Tie2.
IC50 value: 10 nM [1]
Target: Met
in vitro: SU11274 exhibits greater than 50-fold selectivity for Met versus Flk and more than 500 times selectivity versus other tyrosine kinases such as FGFR-1, c-src, PDGFbR, and EGFR. SU11274 inhibits the phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3β. SU11274 treatment inhibits the growth of TPR-MET-transformed BaF3 cells in a dose-dependent manner with IC50 of <3 μM in the absence of interleukin 3, without growth inhibition of BaF3 cells transformed by other oncogenic tyrosine kinases, including BCR-ABL, TEL-JAK2, TEL-ABL, and TEL-PDGFβR. In addition to cell growth, SU11274 treatment significantly inhibits the migration of BaF3. TPR-MET cells by 44.8% and 80% at 1 μM and 5 μM, respectively. SU11274 inhibits HGF-dependent phosphorylation of Met as well as HGF-dependent cell proliferation and motility with an IC50 of 1-1.5 μM. In H69 and H345 cells which have functional Met receptor, SU11274 inhibits the HGF-induced cell growth with IC50 of 3.4 μM and 6.5 μM, respectively. SU11274 induces G1 cell cycle arrest with cells in G1 phase increased from 42.4% to 70.6% at 5 μM, and induces caspase-dependent apoptosis by 24% at 1 μM [2]. SU11274 inhibits cell viability in c-Met-expressing non-small cell lung cancer (NSCLC) cells with IC50 values of 0.8-4.4 μM, and abrogates hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling [3].

Protocol (Extracted from published papers and Only for reference)


Chemical Information

M.Wt 568.09 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C28H30ClN5O4S
CAS No 658084-23-2
Solvent & Solubility

DMSO ≥90mg/mL Water <1.2mg/mL Ethanol ≥1.8mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.7603 mL 8.8014 mL 17.6028 mL
5 mM 0.3521 mL 1.7603 mL 3.5206 mL
10 mM 0.1760 mL 0.8801 mL 1.7603 mL

References on SU11274

Inhibitor Kit

Related c-Met/HGFR Products

  • Altiratinib

    Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.

  • AMG-208

    AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM.

  • AMG-337

    AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.

  • BMS 777607

    BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.

  • BMS-794833

    BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7/15 nM; also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378.

  • c-Met inhibitor 1

    c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

  • E-7050

    E7050(Golvatinib) is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM.

  • EMD-1214063

    EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

  • Foretinib

    Foretinib (GSK1363089; XL880; EXEL-2880; GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFR(alpha)/(beta) and Tie-2, and little activity to FGFR1 and EGFR.

  • INCB28060

    INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase.